The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...
Boehringer Ingelheim has halted development of an obesity drug from Gubra that it originally pledged to advance back in 2017, ...
Abdulla also aims to further strengthen relationships with regional governments and key healthcare stakeholders to ensure sustainable patient access to Boehringer Ingelheim’s portfolio of leading ...
Spending the day facing the challenges of kidney patients helps workers at a CT pharmaceutical company understand disease and ...
Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare ...
Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the oncology-focused platform company’s decision to file for bankruptcy. Notable's ...
The state-of-the-art research and development center in Georgia will help improve the health and wellbeing of animals Boehringer Ingelheim shared earlier this month that it has officially opened the ...
Bayer and Boehringer Ingelheim both had new data on their HER2-targeting small-molecule drugs to present at the World Conference on Lung Cancer (WCLC), hoping to add new oral therapies to the ...
In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and ...
Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...
Boehringer Ingelheim partners with the WHO Foundation to financially support WHO’s Fourteenth General Programme of Work (2025 to 2028). Credit: PeopleImages.com – Yuri A/Shutterstock. Boehringer ...
Recent developments driving growth in this area make the advanced, AI-supported digitization of pharma pipelines inevitable.